FDA records identify Aevice Health Pte., Ltd. as the applicant for two 510(k) submissions. The Aevice Wheeze Detection Module received a substantially equivalent decision on September 25, 2026, under regulation number 21 CFR 868.1900, product code PHZ, with the advisory committee listed as Anesthesiology. The earlier AeviceMD clearance, K223382, was decided July 7, 2023, under 21 CFR 870.2800 with product codes DSH and DQD. The company's own press page describes the wheeze module as standalone software that uses AI to analyze lung sound recordings from compatible FDA-cleared electronic stethoscopes. [1][2][4][8]

The Wheeze Detection Module filing

K260140 was received January 20, 2026, and decided September 25, 2026, as a Traditional 510(k) with a Summary statement and no third-party review. The FDA clearance letter lists the trade name Aevice Wheeze Detection Module, regulation name diagnostic pulmonary-function interpretation calculator, Class II, product code PHZ, and dates the submission August 21, 2026. The applicant address in the filing is 3 Tai Seng Ave., Tai Seng Exchange Tower B #04-32, Singapore. [1][2]

The clearance letter states that software documentation and testing followed FDA guidance on premarket submissions for device software functions, at a Basic Documentation Level, covering requirements, risk management, architecture and design, verification and validation, input validation, error handling, algorithm implementation, output generation and host-system interfaces. The letter records that results demonstrated the software performs as intended and meets its specified requirements. [2]

AeviceMD and its regulatory classification

The 2023 clearance letter for AeviceMD names Aevice Health Pte. Ltd. as applicant, with Adrian Ang as CEO, at 18 Howard Road, #06-11 Novelty Bizcentre, Singapore. The device was classified under 21 CFR 870.2800, regulation name Medical Magnetic Tape Recorder, Class II, product codes DSH and DQD, with the submission dated and received November 7, 2022. [8]

A ClinicalTrials.gov record titled AeviceMD for Detection of Wheeze in Pediatric and Adult Populations appears among the linked sources; the record page text available here does not state enrollment, endpoints or results. [9]

Stated scope and company-published context

Aevice's press page states the wheeze module was cleared as a Class II device for adults and pediatric patients aged two years and older, and that the standalone software automatically flags recordings containing sounds suggestive of wheeze for clinical review. The same page describes wheeze as a high-pitched whistling sound produced as air moves through narrowed airways, occurring in conditions such as asthma, COPD and some respiratory infections. [4]

Aevice's website announces that AeviceMD is available at Parkway MediCentre and that the company partnered with Parkway MediCentre on a paediatric asthma monitoring programme. The site lists CES Innovation Awards 2023 Best of Innovation in Digital Health and Digital Health Awards recognitions in 2023 and 2024. These are company statements, not FDA findings. [6][7]

What the record does and does not establish

The linked collection contains one 510(k) record, K260140, with a substantially equivalent decision; the record sample is that same single entry, so the sample and collection counts coincide at this snapshot. The 2023 AeviceMD letter appears in the numbered sources but not in the linked collection sample. Neither count represents total company sales, total portfolio or safety performance. [1][8]

No linked recall records appear in the collection. Headquarters, ownership structure, parent or brand relationships, customer lists and commercial availability beyond the company's own statements are not established by these sources. [1][4][6]